Bleeding risk of surgical versus medical abortion at 14–16 weeks
Official title: Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions
Run by University Hospital, Strasbourg, France · NCT07335939 · Data updated 2026-11-12
This project tests whether surgical or medical abortion causes less bleeding for adults having an abortion at 14–16 weeks of pregnancy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | May 19, 2025 |
| Main results expected | June 2026 |
| Study ends | June 19, 2026 |
| Registry record updated | January 13, 2026 |
| Trial ID | NCT07335939 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women with a single or multiple ongoing pregnancy who undergo an abortion at 14–16 weeks of gestation at Strasbourg University Hospital between March 2, 2022 and March 2, 2026.
✕Probably not a fit
People with pregnancies under 14 weeks, over 16 weeks, missed pregnancies, or those treated outside CHU Strasbourg or outside the study dates are not included and would not directly benefit from this project's data.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational comparison of hemorrhagic outcomes after surgical versus medical abortion for pregnancies between 14 and 16 weeks at Strasbourg University Hospital. The team will collect clinical data from patients treated between March 2, 2022 and March 2, 2026, including single and multiple pregnancies. Outcomes will focus on rates of bleeding complications and severe hemorrhage associated with each method. Results aim to clarify risks and support method choice in the extended legal time window.
Why it matters
Potential benefit: If successful, the findings could give clearer information to reduce bleeding complications and help people choose the safer method at 14–16 weeks.
How similar studies have gone: Prior research and French guidance generally favor surgical methods after early gestation due to lower bleeding risk, but direct comparative data specifically for 14–16 weeks are limited and mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult woman * Single or multiple pregnancy * Undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026 Exclusion Criteria: * Missed Pregnancy * Term \< 14 Weeks of Gestation or \> 16 Weeks of Gestation
Where it's running
-
Service de Gynécologie-Obstétrique - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Victor Gabrielle, MD
- Email: Victor.gabriele@chru-strasbourg.fr
- Phone: 33 3 69 55 34 04
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.